Weight loss drugs are taking center spotlight, but other developing treatments could change how we live. Deidre Woollard caught up with Motley Fool biotech analyst Karl Thiel to discuss:

- Biogen’s next shot at an Alzheimer’s treatment.
- Why companies can’t “muscle their way” into making new molecules.
- How NVIDIA could change drug development. 
- Moderna’s vaccine strategy

Companies discussed: LLY, NVO, GPCR, NVDA, DXCM, NVDA, BIIB, GEHC, MRNA, NVCR, VRTX

Host: Deidre Woollard
Guest: Karl Thiel
Producer: Ricky Mulvey
Engineer: Tim Sparks
Learn more about your ad choices. Visit megaphone.fm/adchoices